Medical-claims databases in the design of a health-outcomes comparison of quetiapine (`Seroquel'1Seroquel is a trademark, the property of Zeneca Limited.1) and usual-care antipsychotic medication

Hong, Walter W.; Rak, Ihor W; Ciuryla, Vincent; Wilson, Anastasia M; Kylstra, Jelle W; Meltzer, Herbert Y.; Carpenter, William T.; Lehman, Anthony F.; Arvanitis, L.A.

doi:10.1016/s0920-9964(98)00040-1

Cited by 12 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven were cost analyses only (no effectiveness data), 21-27 three were reviews, [28][29][30] one was in Spanish, 31 three reported costs only in terms of hospitalisations, [32][33][34] and six lacked data on costs or outcomes. [35][36][37][38][39][40] Of the 305 unclassified studies excluded, most were because they were non-systematic reviews, had inappropriate study designs or were published comments, letters or editorials.…”

Section: Chaptermentioning

confidence: 99%

“…Eight were cost-analyses only (no effectiveness data), 21-27,882 four were non-systematic reviews, [28][29][30]333 one was in Spanish, 31 two reported costs only in terms of hospitalisations 32,33 and seven were excluded because of lack of data on costs or outcomes. 35,[37][38][39][40]334 A list of excluded studies is presented in appendix 12.…”

Section: Excluded Studiesmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of atypical antipsychotic drugs in schizophrenia

Bagnall

Jones

Ginnelly

et al. 2003

Health Technol Assess

151

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA systematic review of atypical antipsychotic drugs in schizophrenia NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/20/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.Reviews in Health Technology Assessment are termed 'syst...

show abstract

Section: Chaptermentioning

confidence: 99%

Section: Excluded Studiesmentioning

confidence: 99%

A systematic review of atypical antipsychotic drugs in schizophrenia

Bagnall

Jones

Ginnelly

et al. 2003

Health Technol Assess

151

114

View full text Add to dashboard Cite

show abstract

“…QUE and OLA belong to the chemical class of benzisoxazole derivatives and have been found to be effective in the treatment of schizophrenic disorders, with therapeutic activity mediated through a combination of D2 and 5HT2 receptor antagonism [8] . Moreover, it has been shown that they have a very low potential for causing extrapyramidal symptoms (EPS) across the full dose range [9,10] . QUE and OLA may improve cognitive functions (attentional, motor, and visuomotor skills) as well as executive functions connected to the psychopathology of schizophrenia [10] .…”

Section: Introductionmentioning

confidence: 99%

Quetiapine, Olanzapine and Haloperidol Affect Human Plasma Lipid Peroxidation in vitro

2011

View full text Add to dashboard Cite

Objective: Oxidative injury in schizophrenia may be caused not only by pathophysiological processes but partly also by treatment with antipsychotics. The purpose of the present study was to examine and to compare the effects of quetiapine (QUE), olanzapine (OLA) and haloperidol (HAL), at final concentrations corresponding to doses used for treatment of acute episodes of schizophrenia, on plasma lipid peroxidation in vitro, measured by the level of thiobarbituric acid-reactive substances (TBARS). Methods: Blood from 30 healthy volunteers was collected into ACD (citric acid/citrate/dextrose) solution. The drugs in form of active substances were dissolved in 0.01% dimethyl sulfoxide, added to plasma at the final concentrations [QUE (175 and 275 ng/ml), OLA (20 and 40 ng/ml), HAL (4 and 20 ng/ml)] and incubated for 1 and 24 h at 37°C. The level of TBARS was measured spectrophotometrically (according to the Rice-Evans method, 1991). Results: The comparative study in vitro showed that QUE causes a decrease in the TBARS level in plasma, whereas HAL increases the plasma TBARS level. After 24 h of incubation of plasma with QUE or HAL (at lower and higher concentrations),thedifferences in TBARS levels between the drugs were significant (p = 5.9 × 10^–4, p = 2.2 × 10^–5, respectively). Conclusion: QUE and OLA, contrary to the prooxidative action of HAL, did not induce oxidative stress; moreover, QUE has antioxidant properties.

show abstract

“…The authors calculate cost-effectiveness ratios to achieve this benefit and conclude that continuous medication is likely to be a good proxy measure of improved outcome Those with complete claims data and a new prescription of antidepressants were followed up over 12 months from initiation of prescription ( n =2678) Continuous medication use over 6 months is taken to be a proxy measure of effective antidepressant therapy and good outcome (Agency for Health Care Policy Research, 1993) Previous claims, hospitalisations and diagnoses of depression were used to adjust, using logistic regression Total health care costs were also measured from cost claims data Hylan et al (1999) Patients in receipt of pharmacotherapy for depression in primary care settings Is there a difference between different SSRI antidepressants in terms of patient compliance? A commercially available medical insurance database of linked pharmacy and medical claims data on 750 000 individuals Continuous prescription of the same antidepressant, without dosage change, or switch between different drugs or drug classes over 6 months, was taken as a proxy measure of a successful initial choice of antidepressant Logistic regression of available confounders included demographic details; severity of depression from ICD codes; comorbid drug and alcohol problems; comorbid physical disorder (counts of other ICD codes); provider characteristics (primary care or specialist) Patients in receipt of fluoxetine were more likely to receive continuous prescriptions over a 6-month period, when compared with sertraline or paroxetine. The authors conclude that fluoxetine is better-tolerated than either sertraline or paroxetine Complete episodes available on 1034 patients in receipt of a new SSRI prescription Hong et al (1998) US patients with relapsing schizophrenia and high levels of health care resource use Is a newer antipsychotic (quetiapine) associated with better compliance, and therefore lower rates of rehospitalisation, when compared with conventional treatment? Those with schizophren...…”

Section: Resultsmentioning

confidence: 99%